Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
Year: 2018
Type: article
Source: Journal of Thoracic Oncology
Institutions: National Taiwan University Hospital, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Harvard University, Massachusetts General Hospital, Mackay Memorial Hospital, The University of Texas MD Anderson Cancer Center, National Cheng Kung University Hospital, Merck & Co., Inc., Rahway, NJ, USA (United States), South Texas Accelerated Research Therapeutics
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: American Association for Cancer Research, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Bayer, Merck, Novartis, Roche, Cancer Prevention and Research Institute of Texas, Ariad Pharmaceuticals, Celgene, Boehringer Ingelheim, University of South Alabama, Mount Sylvia Diatomite, National Institutes of Health, Genentech, University of Texas MD Anderson Cancer Center, Merck Sharp and Dohme, Pharmaceuticals Bayer, National Cancer Institute
OpenAlex ID: W2903379674